DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.

Humans Male Retrospective Studies Aged Middle Aged Prostatic Neoplasms / drug therapy Recombinational DNA Repair / genetics Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use Mutation DNA Damage Aged, 80 and over

Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 23 8 2024
Statut: ppublish

Résumé

Outcomes data for DNA-damaging therapeutics for men with prostate cancer (PC) and non- Retrospective data from the PROMISE consortium were used. Clinical outcomes differences were assessed between patients with One hundred and forty-six patients received PARPi (cohort A: 94, cohort B: 45, cohort C: 7) and 104 received platinum chemotherapy (cohort A: 48, cohort B: 44, cohort C: 10). PSA50 response rate to PARPi was higher in cohort A (61%) than cohort B (5%), Patients with

Identifiants

DOI: 10.1200/PO.24.00014 PMID: 39178368
pubmed: 39178368
doi: 10.1200/PO.24.00014
doi:

Substances chimiques

Poly(ADP-ribose) Polymerase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400014

Auteurs

Laura S Graham (LS)

University of Colorado, Aurora, CO.
ORCID: 0000-0003-4371-572X

Nicholas C Henderson (NC)

University of Michigan, Ann Arbor, MI.
ORCID: 0000-0003-3184-0945

Olesia Kellezi (O)

University of Michigan, Ann Arbor, MI.
ORCID: 0000-0002-9769-3258

Clara Hwang (C)

Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Cancer Institute, Detroit, MI.
ORCID: 0000-0002-0998-323X

Pedro C Barata (PC)

University Hospitals Seidman Cancer Center, Cleveland, OH.
ORCID: 0000-0002-8890-2951

Mehmet A Bilen (MA)

Winship Cancer Institute of Emory University, Atlanta, GA.
ORCID: 0000-0003-4003-1103

Deepak Kilari (D)

Department of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.

Michael Pierro (M)

Department of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.
ORCID: 0000-0003-1047-7614

Bicky Thapa (B)

Department of Medicine, Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI.
ORCID: 0000-0002-7636-8907

Abhishek Tripathi (A)

Stephenson Cancer Center, Oklahoma City, OK.
ORCID: 0000-0002-5198-0673

George Mo (G)

University of Washington/Fred Hutchinson Cancer Center, Seattle, WA.

Matthew Labriola (M)

Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.
ORCID: 0000-0003-0919-9864

Joseph J Park (JJ)

Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.

Shoshana Rothstein (S)

Karmanos Cancer Institute, Wayne State University, Detroit, MI.

Rohan Garje (R)

Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
ORCID: 0000-0002-7244-5602

Vadim S Koshkin (VS)

Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
ORCID: 0000-0003-2277-8668

Vaibhav G Patel (VG)

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Tanya Dorff (T)

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
ORCID: 0000-0001-5990-298X

Andrew J Armstrong (AJ)

Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.
ORCID: 0000-0001-7012-1754

Rana R McKay (RR)

Moores Cancer Center, University of California San Diego, La Jolla, CA.
ORCID: 0000-0002-0581-7963

Ajjai Alva (A)

University of Michigan, Ann Arbor, MI.

Michael T Schweizer (MT)

University of Washington/Fred Hutchinson Cancer Center, Seattle, WA.
ORCID: 0000-0002-5510-0661

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Phénomènes génétiques › Recombinaison génétique › Recombinaison homologue › Réparation de l'ADN par recombinaison › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › DNA-Damaging Therapies in Patients With...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › DNA-Damaging Therapies in Patients With...